Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma

被引：6

作者：

Sugimoto, Kayo ^{[1
,2
,4
]}

Kim, Soo Ryang ^{[5
]}

Kim, Soo Ki ^{[7
]}

Imoto, Susumu ^{[5
]}

Tohyama, Madoka ^{[5
]}

Kim, Ke Ih ^{[4
]}

Ohtani, Aya ^{[4
]}

Hatae, Takashi ^{[6
]}

Yano, Yoshihiko ^{[3
]}

Kudo, Masatoshi ^{[8
]}

Hayashi, Yoshitake ^{[1
,2
]}

机构：

[1] Kobe Univ, Grad Sch Med, Div Mol Med, Kobe, Hyogo 657, Japan

[2] Kobe Univ, Grad Sch Med, Div Med Genet, Kobe, Hyogo 657, Japan

[3] Kobe Univ, Grad Sch Med, Ctr Infect Dis, Dept Pathol, Kobe, Hyogo 657, Japan

[4] Kobe Asahi Hosp, Dept Pharm, Kobe, Hyogo 6530801, Japan

[5] Kobe Asahi Hosp, Dept Gastroenterol, Kobe, Hyogo 6530801, Japan

[6] Kobe Pharmaceut Univ, Educ Ctr Clin Pharm, Kobe, Hyogo 658, Japan

[7] Kyoto Univ, Dept Gastroenterol & Hepatol, Kyoto, Japan

[8] Kinki Univ, Sch Med, Dept Gastroenterol & Hepatol, Osaka 589, Japan

来源：

ONCOLOGY | 2015年 / 89卷

关键词：

Prevention; Hepatocellular carcinoma; Occurrence; Recurrence; Daclatasvir; Asunaprevir; Direct-acting antivirals; Interferon-free treatment; CHRONIC HEPATITIS-C; INTERFERON THERAPY; VIRUS-INFECTION; RISK; JAPAN; ALPHA;

D O I：

10.1159/000440630

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives:The efficacy of the all-oral administration of daclatasvir and asunaprevir for 24 weeks was compared with that of telaprevir for 12 weeks plus pegylated interferon and ribavirin (PEG-IFN/RBV) for 24 weeks, and that of simeprevir for 12 weeks plus PEG-IFN/RBV for 24 weeks, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma (HCC). The levels of alanine aminotransferase (ALT) and a-fetoprotein (AFP) as suppressive markers of HCC were also measured. Methods: Patients received daclatasvir and asunaprevir (n = 17), simeprevir plus PEG-IFN/RBV (n = 15) and telaprevir plus PEG-IFN/RBV (n = 25). Sustained virological response (SVR) and the mean change in the level of serum ALT, AFP and platelet (PLT) count were compared among the three groups. Results: No difference in SVR was observed in patients given daclatasvir with asunaprevir (SVR4), telaprevir plus PEGIFN/RBV or simeprevir plus PEG-IFN/RBV (SVR24). Also, no significant difference was observed in the mean change of serum ALT, AFP or PLT count among the three groups. Conclusion: The preventive effect of the IFN-free,all-oral regimen of daclatasvir and asunaprevir was observed with a focus on the occurrence and recurrence of HCC, as was IFN-based treatment with telaprevir or simeprevir plus PEG-IFN/RBV. (C) 2015 S. Karger AG, Basel

引用

页码：42 / 46

页数：5

共 26 条

[11] Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C [J].

Imai, Y ;

Kawata, S ;

Tamura, S ;

Yabuuchi, I ;

Noda, S ;

Inada, M ;

Maeda, Y ;

Shirai, Y ;

Fukuzaki, T ;

Kaji, I ;

Ishikawa, H ;

Matsuda, Y ;

Nishikawa, M ;

Seki, K ;

Matsuzawa, Y .

ANNALS OF INTERNAL MEDICINE, 1998, 129 (02) :94-99

[12] Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection [J].

Jacobson, Ira M. ;

McHutchison, John G. ;

Dusheiko, Geoffrey ;

Di Bisceglie, Adrian M. ;

Reddy, K. Rajender ;

Bzowej, Natalie H. ;

Marcellin, Patrick ;

Muir, Andrew J. ;

Ferenci, Peter ;

Flisiak, Robert ;

George, Jacob ;

Rizzetto, Mario ;

Shouval, Daniel ;

Sola, Ricard ;

Terg, Ruben A. ;

Yoshida, Eric M. ;

Adda, Nathalie ;

Bengtsson, Leif ;

Sankoh, Abdul J. ;

Kieffer, Tara L. ;

George, Shelley ;

Kauffman, Robert S. ;

Zeuzem, Stefan .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (25) :2405-2416

[13] Recent Progress in the Treatment and Diagnosis of Hepatocellular Carcinoma [J].

Kokudo, Norihiro .

LIVER CANCER, 2013, 2 (01) :4-4

[14] Adjuvant Therapy after Curative Resection for Hepatocellular Carcinoma Associated with Hepatitis Virus [J].

Kubo, Shoji ;

Takemura, Shigekazu ;

Sakata, Chikaharu ;

Urata, Yorihisa ;

Uenishi, Takahiro .

LIVER CANCER, 2013, 2 (01) :40-46

[15] Prediction of Hepatocellular Carcinoma Incidence Risk by Ultrasound Elastography [J].

Kudo, M. .

LIVER CANCER, 2014, 3 (01) :1-5

[16] Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection [J].

Kumada, Hiromitsu ;

Suzuki, Yoshiyuki ;

Ikeda, Kenji ;

Toyota, Joji ;

Karino, Yoshiyasu ;

Chayama, Kazuaki ;

Kawakami, Yoshiiku ;

Ido, Akio ;

Yamamoto, Kazuhide ;

Takaguchi, Koichi ;

Izumi, Namiki ;

Koike, Kazuhiko ;

Takehara, Tetsuo ;

Kawada, Norifumi ;

Sata, Michio ;

Miyagoshi, Hidetaka ;

Eley, Timothy ;

McPhee, Fiona ;

Damokosh, Andrew ;

Ishikawa, Hiroki ;

Hughes, Eric .

HEPATOLOGY, 2014, 59 (06) :2083-2091

[17]

Kumada T, 1997, HEPATOLOGY, V25, P87, DOI 10.1053/jhep.1997.v25.pm0008985270

[18] Local Ablation for Hepatocellular Carcinoma in Taiwan [J].

Lin, Shi-Ming .

LIVER CANCER, 2013, 2 (02) :73-83

[19] A Worldwide Survey of the Current Daily Practice in Liver Surgery [J].

Mise, Yoshihiro ;

Sakamoto, Yoshihiro ;

Ishizawa, Takeaki ;

Kaneko, Junichi ;

Aoki, Taku ;

Hasegawa, Kiyoshi ;

Sugawara, Yasuhiko ;

Kokudo, Norihiro .

LIVER CANCER, 2013, 2 (01) :55-66

[20] Spread times of hepatitis C virus estimated by the molecular clock differ among Japan, the United States and Egypt in reflection of their distinct socioeconomic backgrounds [J].

Mizokami, M ;

Tanaka, Y ;

Miyakawa, Y .

INTERVIROLOGY, 2005, 49 (1-2) :28-36

← 1 2 3 →